Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuankai Shi

Showing results (91-100 of 347) with videos related to

Pageof 35
Sort By:
BMC Cancer|April 24, 2025
Pretreatment plasma sCD14 as a prognostic indicator in advanced non-small cell lung cancer patients undergoing immunotherapyLiyuan Dai, Liling Huang, Lin Li, et al.
Chinese Medical Journal|February 25, 2026
Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026)Zucheng Xie, Xinrui Chen, Ruyun Gao, et al.
Scientific Reports|April 15, 2016
Prognostic impact of mutation profiling in patients with stage II and III colon cancerYinchen Shen, Xiaohong Han, Jianfei Wang, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|June 1, 2016
Development and validation of a UHPLC-MS/MS method for simultaneous quantitation the plasma concentration of Sabarubicin and its alcohol metabolite M3 in Chinese small cell lung cancer patientsYan Zhang, Peng Liu, Ning Li, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 28, 2020
Development of an LC-MS/MS method for quantifying ASK120067, a novel mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) as well as its main metabolite in human plasma and its application in a pharmacokinetic studyXinge Cui, Shaoyuan Wang, Huitao Gao, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|October 12, 2013
[Local treatment combined with EGFR-TKIs for advanced non-small cell lung cancer with solitary progression during EGFR-TKI treatment]Xin Zhang, Bin Wang, Lin Lin, et al.
Immunotherapy|January 30, 2023
Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysisYu Zhou, Haizhu Chen, Le Tang, et al.
Clinical Lung Cancer|January 7, 2026
Efficacy and Safety of Firmonertinib Plus Anlotinib as First-Line Treatment for Advanced NSCLC With EGFR Mutations: A Single-Arm, Phase I/II TrialHuiyang Shi, Haohua Zhu, Le Tang, et al.
Oncology Reports|April 12, 2011
Aurora-A as an independent molecular prognostic marker in gastric cancerJing Wang, Sheng Yang, Haizeng Zhang, et al.
Disease Markers|November 1, 2022
DLX2 Is a Potential Immune-Related Prognostic Indicator Associated with Remodeling of Tumor Microenvironment in Lung Squamous Cell Carcinoma: An Integrated Bioinformatical AnalysisLiling Huang, Tongji Xie, Fuqiang Zhao, et al.
Pageof 35

Showing results (91-100 of 347) with videos related to

Sort By:
Pageof 35
BMC Cancer|April 24, 2025
Pretreatment plasma sCD14 as a prognostic indicator in advanced non-small cell lung cancer patients undergoing immunotherapyLiyuan Dai, Liling Huang, Lin Li, et al.
Chinese Medical Journal|February 25, 2026
Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026)Zucheng Xie, Xinrui Chen, Ruyun Gao, et al.
Scientific Reports|April 15, 2016
Prognostic impact of mutation profiling in patients with stage II and III colon cancerYinchen Shen, Xiaohong Han, Jianfei Wang, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|June 1, 2016
Development and validation of a UHPLC-MS/MS method for simultaneous quantitation the plasma concentration of Sabarubicin and its alcohol metabolite M3 in Chinese small cell lung cancer patientsYan Zhang, Peng Liu, Ning Li, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 28, 2020
Development of an LC-MS/MS method for quantifying ASK120067, a novel mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) as well as its main metabolite in human plasma and its application in a pharmacokinetic studyXinge Cui, Shaoyuan Wang, Huitao Gao, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|October 12, 2013
[Local treatment combined with EGFR-TKIs for advanced non-small cell lung cancer with solitary progression during EGFR-TKI treatment]Xin Zhang, Bin Wang, Lin Lin, et al.
Immunotherapy|January 30, 2023
Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysisYu Zhou, Haizhu Chen, Le Tang, et al.
Clinical Lung Cancer|January 7, 2026
Efficacy and Safety of Firmonertinib Plus Anlotinib as First-Line Treatment for Advanced NSCLC With EGFR Mutations: A Single-Arm, Phase I/II TrialHuiyang Shi, Haohua Zhu, Le Tang, et al.
Oncology Reports|April 12, 2011
Aurora-A as an independent molecular prognostic marker in gastric cancerJing Wang, Sheng Yang, Haizeng Zhang, et al.
Disease Markers|November 1, 2022
DLX2 Is a Potential Immune-Related Prognostic Indicator Associated with Remodeling of Tumor Microenvironment in Lung Squamous Cell Carcinoma: An Integrated Bioinformatical AnalysisLiling Huang, Tongji Xie, Fuqiang Zhao, et al.
Pageof 35